Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

WINT

Windtree Therapeutics Inc

Last Close
Apr 25 • 04:00PM ET
5.07
Dollar change
-0.08
Percentage change
-1.65 		%
Held by: VXF
Index- P/E- EPS (ttm)-146.17 Insider Own16.82% Shs Outstand0.51M Perf Week-17.11%
Market Cap2.59M Forward P/E- EPS next Y- Insider Trans- Shs Float0.42M Perf Month-20.36%
Income-20.29M PEG- EPS next Q-0.55 Inst Own2.94% Short Float0.61% Perf Quarter-37.04%
Sales0.00M P/S- EPS this Y- Inst Trans43.25% Short Ratio0.16 Perf Half Y-74.62%
Book/sh10.18 P/B0.50 EPS next Y- ROA-57.68% Short Interest0.00M Perf Year-84.86%
Cash/sh8.47 P/C0.60 EPS next 5Y- ROE-302.78% 52W Range4.78 - 38.88 Perf YTD-60.82%
Dividend Est.- P/FCF- EPS past 5Y66.05% ROI-103.78% 52W High-86.96% Beta0.61
Dividend TTM- Quick Ratio1.35 Sales past 5Y-37.79% Gross Margin- 52W Low6.13% ATR (14)0.78
Dividend Ex-Date- Current Ratio1.35 EPS Y/Y TTM87.13% Oper. Margin0.00% RSI (14)33.21 Volatility12.39% 13.42%
Employees15 Debt/Eq4.96 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price18.00
Option/ShortNo / Yes LT Debt/Eq4.77 EPS Q/Q93.15% Payout- Rel Volume0.79 Prev Close5.16
Sales Surprise- EPS Surprise-1.06% Sales Q/Q- EarningsApr 17 BMO Avg Volume15.81K Price5.07
SMA20-24.40% SMA50-22.91% SMA200-65.98% Trades Volume12,471 Change-1.65%
Date Action Analyst Rating Change Price Target Change
Jun-26-20Initiated Ladenburg Thalmann Buy $12.25
Apr-18-24 08:00AM
Windtree Therapeutics Announces Reverse Stock Split
(GlobeNewswire) -15.32%
Apr-17-24 08:00AM
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
(GlobeNewswire)
06:52AM
WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023
(InvestorPlace)
Apr-08-24 04:48PM
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
(GlobeNewswire)
Feb-01-24 08:00AM
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
(GlobeNewswire)
08:00AM Loading…
Jan-31-24 08:00AM
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
(GlobeNewswire) -6.60%
Jan-26-24 09:20AM
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
(ACCESSWIRE)
Jan-25-24 08:30AM
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
(GlobeNewswire)
Jan-18-24 09:00AM
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
(ACCESSWIRE)
Jan-17-24 08:00AM
Windtree Therapeutics Announces License Agreement with Lees Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
(GlobeNewswire) -18.04%
Jan-02-24 04:05PM
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
(GlobeNewswire)
Dec-19-23 09:30AM
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
(ACCESSWIRE)
Dec-18-23 08:00AM
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire)
Nov-16-23 08:00AM
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
(GlobeNewswire)
Nov-14-23 08:55AM
Sidoti Events, LLCs Virtual November Micro-Cap Conference
(ACCESSWIRE)
04:15PM Loading…
Nov-09-23 04:15PM
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Nov-08-23 08:00AM
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
(GlobeNewswire)
Oct-12-23 07:30AM
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
(GlobeNewswire) +18.42%
Oct-10-23 07:30AM
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
(GlobeNewswire)
Oct-03-23 08:00AM
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
(GlobeNewswire)
Sep-21-23 09:35AM
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
(GlobeNewswire)
Aug-25-23 07:20AM
7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole
(InvestorPlace) -7.02%
Aug-23-23 08:00AM
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
(GlobeNewswire)
Aug-16-23 09:00AM
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
(ACCESSWIRE)
Aug-07-23 04:05PM
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Jul-25-23 09:25AM
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
(ACCESSWIRE)
Jul-18-23 09:00AM
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
(ACCESSWIRE)
Jul-14-23 09:00AM
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That
(ACCESSWIRE)
Jun-27-23 08:00AM
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
(GlobeNewswire)
Jun-12-23 08:00AM
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
(GlobeNewswire) -5.08%
08:00AM Loading…
Jun-05-23 08:00AM
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
(GlobeNewswire) +8.63%
May-15-23 04:30PM
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
(GlobeNewswire)
May-11-23 12:20PM
10 Best Stocks to Buy for a Quick Return
(Insider Monkey)
Apr-27-23 08:00AM
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
(GlobeNewswire)
Apr-24-23 04:01PM
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
(GlobeNewswire)
Apr-20-23 08:30AM
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
(GlobeNewswire) -57.68%
Apr-17-23 08:00AM
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent
(GlobeNewswire) +88.81%
Apr-03-23 07:35AM
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Mar-13-23 08:00AM
Windtree Regains Compliance with Nasdaq
(GlobeNewswire)
Mar-06-23 08:00AM
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime
(GlobeNewswire)
Feb-28-23 08:00AM
Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure
(GlobeNewswire)
Feb-27-23 08:00AM
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference
(GlobeNewswire) -8.99%
Feb-24-23 08:00AM
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
(GlobeNewswire) -15.85%
Feb-23-23 12:00PM
Windtree Therapeutics Announces Reverse Stock Split
(GlobeNewswire) -34.40%
Jan-20-23 08:37AM
Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants
(GlobeNewswire) -25.65%
Dec-05-22 07:30AM
Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance
(GlobeNewswire) -5.43%
Nov-18-22 12:00PM
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why
(Zacks)
Nov-14-22 07:30AM
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Oct-25-22 08:00AM
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
(GlobeNewswire)
Oct-06-22 06:50AM
Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders
(Simply Wall St.)
Sep-29-22 07:45AM
Windtree Therapeutics Stock Surges After Positive Istaroxime Data In Cardiogenic Shock
(Benzinga) +6.15%
Sep-28-22 04:05PM
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure
(GlobeNewswire)
Sep-26-22 08:00AM
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America
(GlobeNewswire)
Sep-21-22 04:05PM
Windtree to Present at the Ladenburg Thalmann Healthcare Conference
(GlobeNewswire) -6.13%
Sep-06-22 04:05PM
Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference
(GlobeNewswire)
Aug-24-22 02:59PM
Windtree Therapeutics out-licenses surfactant platform in a deal that could be worth nearly $80M
(American City Business Journals) -28.14%
Aug-23-22 08:00AM
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
(GlobeNewswire) +52.21%
Aug-11-22 04:05PM
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Jun-29-22 08:00AM
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value
(GlobeNewswire)
May-23-22 10:12AM
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid
(GlobeNewswire) -11.25%
May-16-22 07:00AM
Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire) +6.82%
May-05-22 04:05PM
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Apr-20-22 04:05PM
Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference
(GlobeNewswire)
07:00AM
Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire)
Mar-31-22 04:05PM
Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference
(GlobeNewswire)
03:26PM
Insiders who purchased Windtree Therapeutics, Inc. (NASDAQ:WINT) stock last year recover some losses which currently stand at US$47k
(Simply Wall St.)
07:05AM
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Mar-22-22 01:47PM
Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress
(Benzinga)
07:30AM
Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury
(GlobeNewswire)
Mar-15-22 12:06PM
Windtree Therapeutics Concludes Enrollment In Mid-Stage Cardiogenic Shock Study, Data Expected In April
(Benzinga)
07:00AM
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
(GlobeNewswire)
Mar-10-22 08:00AM
Windtree to Present at Oppenheimers 32nd Annual Healthcare Conference
(GlobeNewswire)
Feb-01-22 02:36PM
Why Are Windtree Therapeutics Shares Trading Higher Today?
(Benzinga) +15.93%
07:30AM
Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome
(GlobeNewswire)
Dec-15-21 08:00AM
Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent
(GlobeNewswire)
Nov-22-21 04:59PM
2 Moonshot Biotechs with 10x Potential
(InvestorPlace)
08:00AM
Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay Adding to Previously Reported Need for New Pharmacologic Innovation
(GlobeNewswire)
Nov-10-21 04:05PM
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Oct-26-21 10:33AM
3 Moonshot Stocks Insiders Are Buying and 2 That Are Getting Dumped
(InvestorPlace)
08:51AM
2 Penny Stocks Insiders Are Buying
(Benzinga)
Oct-25-21 07:30AM
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
(GlobeNewswire)
Oct-20-21 07:36AM
3 Penny Stocks Insiders Are Buying
(Benzinga) +5.79%
Oct-14-21 07:30AM
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock
(GlobeNewswire)
Oct-12-21 07:30AM
Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study
(GlobeNewswire)
Sep-30-21 02:25PM
Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders
(Simply Wall St.)
Sep-16-21 07:30AM
Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
(GlobeNewswire)
Aug-05-21 04:01PM
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
(GlobeNewswire)
Aug-02-21 08:00AM
Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management
(GlobeNewswire)
Jul-08-21 11:20AM
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
(ACCESSWIRE)
07:30AM
Windtree to Present at Access to Giving Virtual Investor Conference
(GlobeNewswire)
Jul-07-21 07:30AM
Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)
(GlobeNewswire)
Jul-01-21 07:30AM
Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
(PR Newswire)
Jun-23-21 09:35AM
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
(ACCESSWIRE) +5.16%
Jun-09-21 06:40AM
Most Shareholders Will Probably Agree With Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation
(Simply Wall St.)
May-13-21 07:30AM
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
(PR Newswire) -15.15%
Apr-19-21 07:00AM
Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent
(PR Newswire)
Apr-09-21 02:16PM
7 Beaten Down Stocks with Significant Insider Buying
(InvestorPlace)
Mar-30-21 10:13AM
Have Insiders Been Buying Windtree Therapeutics, Inc. (NASDAQ:WINT) Shares This Year?
(Simply Wall St.) -6.55%
Mar-29-21 05:10PM
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
(PR Newswire) -5.37%
Mar-25-21 04:15PM
Windtree Therapeutics Announces Closing of $30.0 Million Public Offering
(PR Newswire)
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fraser CraigPresident and CEOSep 27 '23Buy1.022,5002,55057,877Sep 28 07:24 AM
Fraser CraigPresident and CEOSep 26 '23Buy0.902,5002,25055,377Sep 27 07:34 AM
Fraser CraigPresident and CEOApr 26 '23Buy1.771,4972,6507,010Apr 27 07:41 AM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

TRVN

Trevena Inc

Last Close
Apr 25 • 04:00PM ET
0.4090
Dollar change
+0.0280
Percentage change
7.35 		%
TRVN Trevena Inc daily Stock Chart
Held by: VXF
Index- P/E- EPS (ttm)-3.13 Insider Own2.41% Shs Outstand18.32M Perf Week11.75%
Market Cap7.49M Forward P/E- EPS next Y-1.35 Insider Trans0.00% Shs Float17.88M Perf Month-7.74%
Income-40.27M PEG- EPS next Q-0.47 Inst Own7.97% Short Float0.33% Perf Quarter-36.51%
Sales3.13M P/S2.39 EPS this Y45.57% Inst Trans-3.48% Short Ratio0.28 Perf Half Y-25.64%
Book/sh-0.44 P/B- EPS next Y21.22% ROA-90.21% Short Interest0.06M Perf Year-34.56%
Cash/sh1.80 P/C0.23 EPS next 5Y- ROE-1014.13% 52W Range0.30 - 3.28 Perf YTD-43.36%
Dividend Est.- P/FCF- EPS past 5Y21.28% ROI-146.04% 52W High-87.53% Beta1.12
Dividend TTM- Quick Ratio4.66 Sales past 5Y2058.58% Gross Margin22.52% 52W Low36.29% ATR (14)0.04
Dividend Ex-Date- Current Ratio4.66 EPS Y/Y TTM59.40% Oper. Margin-1128.89% RSI (14)46.47 Volatility13.98% 11.63%
Employees23 Debt/Eq- Sales Y/Y TTM1194.50% Profit Margin-1288.26% Recom1.00 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-44.50% Payout- Rel Volume0.55 Prev Close0.38
Sales Surprise-156.45% EPS Surprise-178.95% Sales Q/Q- EarningsApr 01 BMO Avg Volume207.95K Price0.41
SMA203.05% SMA50-16.84% SMA200-37.70% Trades Volume114,785 Change7.35%
Date Action Analyst Rating Change Price Target Change
Mar-15-21Initiated Oppenheimer Perform
Sep-14-20Initiated Guggenheim Buy $5
Aug-28-20Initiated Cantor Fitzgerald Overweight $5
May-31-19Resumed H.C. Wainwright Buy
Nov-05-18Downgrade H.C. Wainwright Buy → Neutral
Oct-12-18Downgrade Needham Buy → Hold
Oct-10-18Downgrade Jefferies Buy → Hold
Nov-08-17Reiterated Needham Buy $9 → $7
Oct-16-17Downgrade Barclays Overweight → Equal Weight $15 → $2.50
Oct-12-17Reiterated H.C. Wainwright Buy $8 → $7
Show Previous Ratings
Apr-01-24 07:13AM
Trevena: Q4 Earnings Snapshot
(Associated Press Finance) -13.04%
07:00AM
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
(GlobeNewswire)
Dec-28-23 02:00PM
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
(GlobeNewswire)
Dec-27-23 09:10AM
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
(GlobeNewswire)
Dec-04-23 07:02AM
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
(GlobeNewswire)
07:00AM Loading…
07:00AM
Trevena Awarded OLINVYK Agreement with Premier, Inc.
(GlobeNewswire)
Nov-30-23 07:00AM
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
(GlobeNewswire)
Nov-15-23 03:08PM
Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-14-23 07:35AM
Trevena: Q3 Earnings Snapshot
(Associated Press Finance)
07:00AM
Trevena Reports Third Quarter 2023 Results and Provides Business Update
(GlobeNewswire)
Nov-09-23 07:00AM
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
(GlobeNewswire)
Oct-16-23 07:00AM
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
(GlobeNewswire) +7.14%
Oct-02-23 07:00AM
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
(GlobeNewswire)
Sep-06-23 07:01AM
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
(GlobeNewswire) +14.27%
07:00AM
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
(GlobeNewswire)
07:07AM Loading…
Aug-14-23 07:07AM
Trevena: Q2 Earnings Snapshot
(Associated Press Finance) +5.84%
07:00AM
Trevena Reports Second Quarter 2023 Results and Provides Business Update
(GlobeNewswire)
Jul-20-23 07:00AM
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
(GlobeNewswire)
Jun-26-23 07:00AM
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
(GlobeNewswire)
May-31-23 07:00AM
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
(GlobeNewswire)
May-30-23 07:00AM
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones
(GlobeNewswire)
May-15-23 09:01PM
Q1 2023 Trevena Inc Earnings Call
(Thomson Reuters StreetEvents) -12.59%
07:17AM
Trevena: Q1 Earnings Snapshot
(AP Finance)
07:00AM
Trevena Reports First Quarter 2023 Results and Provides Business Update
(GlobeNewswire)
May-11-23 05:25PM
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
(Zacks) -5.00%
May-09-23 07:00AM
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
(GlobeNewswire) -43.09%
May-08-23 07:00AM
Trevena Announces Approval of OLINVYK in China
(GlobeNewswire) +393.65%
May-03-23 07:00AM
Trevena to Participate in Three Upcoming Conferences
(GlobeNewswire) +7.61%
Apr-09-23 07:34PM
Trevena, Inc. (NASDAQ:TRVN) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-30-23 07:02AM
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
(GlobeNewswire)
07:00AM Loading…
07:00AM
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
(GlobeNewswire)
Mar-27-23 07:00AM
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
(GlobeNewswire) +15.84%
Mar-09-23 10:21AM
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
(Zacks)
Mar-07-23 07:00AM
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders
(GlobeNewswire)
Feb-14-23 08:00AM
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
(GlobeNewswire)
Jan-09-23 07:00AM
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement
(GlobeNewswire)
Dec-08-22 07:00AM
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
(GlobeNewswire)
Nov-29-22 07:00AM
Trevena Regains Compliance with Nasdaq Listing Requirements
(GlobeNewswire)
Nov-16-22 08:00AM
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
Nov-09-22 04:01PM
Trevena Announces Reverse Stock Split
(GlobeNewswire) -30.74%
08:25AM
Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
07:02AM
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
(GlobeNewswire)
07:00AM
Trevena Reports Third Quarter 2022 Results and Provides Business Update
(GlobeNewswire)
Nov-07-22 07:00AM
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
(GlobeNewswire)
Oct-24-22 07:00AM
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
(GlobeNewswire)
Sep-07-22 07:00AM
Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference
(GlobeNewswire)
Aug-16-22 12:00PM
What Makes Trevena (TRVN) a New Buy Stock
(Zacks)
Aug-12-22 06:48AM
We're A Little Worried About Trevena's (NASDAQ:TRVN) Cash Burn Rate
(Simply Wall St.) +5.34%
Aug-11-22 08:25AM
Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates
(Zacks)
07:00AM
Trevena Reports Second Quarter 2022 Results and Provides Business Update
(GlobeNewswire)
Aug-08-22 07:00AM
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
(GlobeNewswire)
Jul-29-22 05:27PM
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock
(GlobeNewswire) -5.67%
08:00AM
Trevena, Inc. Announces Registered Direct Offering of Preferred Stock
(GlobeNewswire)
Jul-28-22 09:41AM
Trevena's Pain Management Drug Shows Better Cognitive Function Than Morphine
(Benzinga)
07:00AM
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
(GlobeNewswire)
Jun-14-22 07:00AM
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care
(GlobeNewswire)
Jun-10-22 07:00AM
Trevena to Participate at the JMP Securities Life Sciences Conference
(GlobeNewswire)
May-18-22 04:05PM
Trevena to Present at the H.C. Wainwright Global Investment Conference
(GlobeNewswire)
May-11-22 08:15AM
Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates
(Zacks) -31.82%
07:00AM
Trevena Reports First Quarter 2022 Results and Provides Business Update
(GlobeNewswire)
May-10-22 07:55AM
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) +13.70%
May-09-22 07:00AM
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
(GlobeNewswire)
Apr-28-22 03:02PM
Analysts Estimate Trevena (TRVN) to Report a Decline in Earnings: What to Look Out for
(Zacks)
Apr-20-22 07:00AM
Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects
(GlobeNewswire)
Apr-18-22 07:00AM
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund
(GlobeNewswire) -7.42%
Apr-13-22 04:05PM
OLINVYK® data selected as Presidents Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting
(GlobeNewswire)
Mar-31-22 11:26AM
Trevena shares skyrocket on $40 million royalty-based financing deal
(American City Business Journals) +24.64%
08:15AM
Trevena (TRVN) Reports Q4 Loss, Lags Revenue Estimates
(Zacks)
07:02AM
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
(GlobeNewswire)
07:00AM
Trevena Reports Fourth Quarter and Full Year 2021 Results
(GlobeNewswire)
Mar-30-22 07:00AM
Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
(GlobeNewswire)
Mar-14-22 08:15AM
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Misses Revenue Estimates
(Zacks)
Mar-07-22 06:55PM
Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
Mar-05-22 06:43AM
Is Trevena (NASDAQ:TRVN) In A Good Position To Invest In Growth?
(Simply Wall St.)
Feb-03-22 07:00AM
Trevena to Present at the 2022 BIO CEO & Investor Conference
(GlobeNewswire)
Jan-28-22 02:01PM
Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City
(American City Business Journals)
Jan-27-22 09:00AM
Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical
(GlobeNewswire) -5.40%
Jan-03-22 04:05PM
Trevena to Participate in the Upcoming January Conferences
(GlobeNewswire) +6.97%
Dec-14-21 11:06AM
Trevena (TRVN) to Begin Clinical Study on Pain Candidate
(Zacks)
Dec-13-21 07:00AM
Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
(GlobeNewswire)
Nov-15-21 12:25PM
Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates
(Zacks) -9.09%
07:00AM
Trevena Reports Third Quarter 2021 Results
(GlobeNewswire)
Nov-11-21 07:00AM
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
(GlobeNewswire)
Nov-08-21 07:00AM
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
(GlobeNewswire) -6.69%
Oct-25-21 03:01PM
Earnings Preview: Trevena (TRVN) Q3 Earnings Expected to Decline
(Zacks)
Oct-13-21 07:00AM
Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021
(GlobeNewswire)
Oct-01-21 10:40AM
Is Trevena Stock a Buy Right Now? This Is What You Need to Know
(TipRanks)
Sep-30-21 09:13AM
Trevena Posts TRV027 Proof-of-Concept Study In Hospitalized COVID-19 Patients
(Benzinga)
07:00AM
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
(GlobeNewswire)
Sep-17-21 07:00AM
Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
(GlobeNewswire) +11.48%
Sep-09-21 07:00AM
Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
(GlobeNewswire)
Aug-30-21 07:00AM
Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021
(GlobeNewswire)
Aug-25-21 07:00AM
Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study
(GlobeNewswire)
Aug-20-21 09:05AM
New Strong Sell Stocks for August 20th
(Zacks)
Aug-12-21 09:55AM
Trevena (TRVN) Reports Q2 Loss, Misses Revenue Estimates
(Zacks) -10.71%
07:00AM
Trevena Reports Second Quarter 2021 Results
(GlobeNewswire)
Aug-10-21 07:00AM
Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy
(GlobeNewswire)
Aug-09-21 07:00AM
Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021
(GlobeNewswire)
Jul-26-21 07:00AM
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19
(GlobeNewswire) -5.44%
Jul-23-21 07:00AM
Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote For All Proposals Ahead of Special Meeting of Stockholders
(GlobeNewswire) -5.77%
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.